semaj83/ctmatch_classification huggingface dataset:
Patient description: The patients is a 25-year-old G1 P1 pregnant woman who is 24W3D gestational old who developed a sudden unset of fever and chills, accompany with nausea and vomiting. She also complains of dysuria, urgency and frequency. She also reports some severe pain in the flank. Her vital signs are: T = 39.7ºC, P = 117, R = 20, and BP = 113/74 mm Hg. Physical examination reveals tenderness on palpation of both costovertebral angles. She has no history of recurrent UTI prior to her pregnancy or any other underlying disease. The urine culture showed Gram-negative rod-shaped bacterial cells, leukocytes, and leukocyte casts. The blood culture is negative. A CBC shows Hb 12.9 g/dL, Hct 39%, MCV 76 fL, WBC count 14,120/µL.

Clinical trial eligibility criteria: eligible ages (years): 15.0-38.0,  Malaria A pregnant woman who has either a positive blood smear for P.falciparum with at least 1000 asexual parasites/uL in an asymptomatic woman or any of the following symptoms within 2 days prior to consultation history of fever headache vomiting chills/rigors and/or any of the following signs: temperature >37.50C and <39.50C, Hb>5 and <9 g/dl together with P.falciparum parasitaemia at any density and (in both cases) the following: 1. Has no criterion (see below); 2. Is 14-34 weeks pregnant on the day of attending the ANC clinic or OPD; 3. Has a viable foetus, defined by presence of foetal heartbeat by sonicaid or pinnard (foetal heartbeat is not heard until 14 weeks); 4. Is able to take study drugs by the oral route; 5. Is able to attend stipulated days for follow up clinic and provide specimens; 6. Gives informed written or witnessed verbal consent to participate by herself, and also through her parent/guardian if aged <15 years (in conformity to Tanzania Law)  Severe and complicated forms of malaria (as defined by WHO, 1996); 2. Pregnancy in the first trimester; 3. A mixed plasmodial infection; 4. Complicated pregnancy, e.g. signs/symptoms of toxaemia of pregnancy; 5. 23 or more abortions or stillbirths; 6. Presence of concomitant disease masking assessment of the response to treatment ; 7. An intake of drugs contraindicated in pregnancy, e.g. tetracycline, cotrimoxazole or a macrolide antibiotic; 8. An intake of drugs with effective antimalarial activity within the last 2 weeks. 9. Significantly abnormal baseline haematology (except anaemia) or clinical chemistry parameters, e.g. laboratory evidence of renal impairment (serum creatinine >2 mg/dl) or of hepatitis (alanine aminotransferase [ALT] >5 times upper limit of normal); 10. Previous participation in the study: Women having a second episode of malaria after completing the 28-day follow up will have details recorded and offered quinine but not be re-enrolled. 11. Multiple gestation pregnancies, eg twins 12. Mother aged 38 years or above
Patient description: The patients is a 25-year-old G1 P1 pregnant woman who is 24W3D gestational old who developed a sudden unset of fever and chills, accompany with nausea and vomiting. She also complains of dysuria, urgency and frequency. She also reports some severe pain in the flank. Her vital signs are: T = 39.7ºC, P = 117, R = 20, and BP = 113/74 mm Hg. Physical examination reveals tenderness on palpation of both costovertebral angles. She has no history of recurrent UTI prior to her pregnancy or any other underlying disease. The urine culture showed Gram-negative rod-shaped bacterial cells, leukocytes, and leukocyte casts. The blood culture is negative. A CBC shows Hb 12.9 g/dL, Hct 39%, MCV 76 fL, WBC count 14,120/µL.

Clinical trial eligibility criteria: eligible ages (years): 21.0-70.0,  COPD Emphysema Chronic Bronchitis Healthy Non-Smoking Subjects. All normal volunteers will meet the following Age 21-70 years No history of respiratory or allergic disease Normal baseline spirometry as predicted for age, sex and height Non-smokers No history of upper respiratory tract infection in the preceding six weeks Not taking regular medication COPD Subjects. COPD is diagnosed according to American Thoracic Society, European Respiratory Society and British Thoracic Society guidelines. All COPD volunteers will meet the following Age between 40-75 years A smoking history of at least 20 pack years. (1 pack year = 20 packs of cigarettes per day for 1 year)  Subjects will not be included in this study if they meet any of the following Clinically significant findings in the medical history or on physical examination other than those of COPD in the COPD group Pregnant women or mothers who are breastfeeding Subjects who are unable to give informed consent
Patient description: The patients is a 25-year-old G1 P1 pregnant woman who is 24W3D gestational old who developed a sudden unset of fever and chills, accompany with nausea and vomiting. She also complains of dysuria, urgency and frequency. She also reports some severe pain in the flank. Her vital signs are: T = 39.7ºC, P = 117, R = 20, and BP = 113/74 mm Hg. Physical examination reveals tenderness on palpation of both costovertebral angles. She has no history of recurrent UTI prior to her pregnancy or any other underlying disease. The urine culture showed Gram-negative rod-shaped bacterial cells, leukocytes, and leukocyte casts. The blood culture is negative. A CBC shows Hb 12.9 g/dL, Hct 39%, MCV 76 fL, WBC count 14,120/µL.

Clinical trial eligibility criteria: eligible ages (years): 21.0-70.0,  COPD Emphysema Healthy non-smoking subjects All normal volunteers will meet the following Age 21-70 years No history of respiratory or allergic disease Normal baseline spirometry as predicted for age, sex and height Non-smokers No history of upper respiratory tract infection in the preceding six weeks Not taking regular medication COPD subjects COPD is diagnosed according to American Thoracic Society, European Respiratory Society and British Thoracic Society guidelines by the doctors in Professor Barnes' COPD clinic. All COPD volunteers will meet the following Age between 40-75 years A smoking history of at least 20 pack years. ( 1 pack year = 20 cigarettes per day for 1 year) FEV1:FVC ratio of <0.7, post-bronchodilator FEV1 of <85% predicted, reversibility with inhaled beta2-agonist of <15% of predicted FEV1: all three are required  Subjects will not included in this study if they meet any of the following Clinically significant findings in the medical history or on physical examination other than those of COPD in the COPD group Pregnant women or mothers who are breastfeeding Subjects who are unable to give informed consent
Patient description: The patients is a 25-year-old G1 P1 pregnant woman who is 24W3D gestational old who developed a sudden unset of fever and chills, accompany with nausea and vomiting. She also complains of dysuria, urgency and frequency. She also reports some severe pain in the flank. Her vital signs are: T = 39.7ºC, P = 117, R = 20, and BP = 113/74 mm Hg. Physical examination reveals tenderness on palpation of both costovertebral angles. She has no history of recurrent UTI prior to her pregnancy or any other underlying disease. The urine culture showed Gram-negative rod-shaped bacterial cells, leukocytes, and leukocyte casts. The blood culture is negative. A CBC shows Hb 12.9 g/dL, Hct 39%, MCV 76 fL, WBC count 14,120/µL.

Clinical trial eligibility criteria: eligible ages (years): 8.0-17.0,  Diabetes Mellitus, Type I Clinical diagnosis of type 1 diabetes for at least 18 months (The diagnosis of type 1 diabetes is based on the investigator's judgment; C peptide level and antibody determinations are not needed.) HbA1c <10.0% (The DCA2000 will be used to assess eligibility.) Age 8.0 to <18.0 years Weight >39.5 kg at reinfusion centers and >46.0 kg at discard centers BMI >5th and <95th percentiles for age and gender Stable insulin regimen for at least 1 month and not anticipating a change prior to the subject's completion of the study (Stable is defined as no change in the overall insulin program, i.e., no change from SC injections to pump.) Insulin regimen involves use of an insulin pump Normal thyroid function (measured within the previous year)  A recent injury to body or limb, Addison's disease, muscular disorder, use of any medication or other significant medical disorder if that injury, medication or disease in the judgment of the investigator will affect the completion of the exercise protocol Asthma which has been medically treated within the last year Current use of glucocorticoid medication (by any route of administration) Current use of a beta blocker medication Use of pseudoephedrine 48 hours prior to visit (if used in the 48 hours prior to the scheduled visit, the visit will be deferred) Severe hypoglycemia resulting in seizure or loss of consciousness in the 2 weeks prior to a visit (if a severe episode occurs within 2 weeks prior to the scheduled visit, the visit will be deferred) Active infection (if at the time of the scheduled visit an infection is present, the visit will be deferred) Anticipating a significant change in exercise regimen between visits (i.e. starting or stopping an organized sport)
Patient description: The patients is a 25-year-old G1 P1 pregnant woman who is 24W3D gestational old who developed a sudden unset of fever and chills, accompany with nausea and vomiting. She also complains of dysuria, urgency and frequency. She also reports some severe pain in the flank. Her vital signs are: T = 39.7ºC, P = 117, R = 20, and BP = 113/74 mm Hg. Physical examination reveals tenderness on palpation of both costovertebral angles. She has no history of recurrent UTI prior to her pregnancy or any other underlying disease. The urine culture showed Gram-negative rod-shaped bacterial cells, leukocytes, and leukocyte casts. The blood culture is negative. A CBC shows Hb 12.9 g/dL, Hct 39%, MCV 76 fL, WBC count 14,120/µL.

Clinical trial eligibility criteria: eligible ages (years): 18.0-50.0,  Pregnancy Toxemia Hypertension Proteinuria Pregnant patients will be evaluated for recruitment to 13 6/7 weeks gestation. 2. Age 18-50 3. Patients will be included for consideration to enter this trial if office blood pressure is >140/90 mm Hg: systolic >140 mm Hg, diastolic >90 mm Hg or both. The average of 3 readings taken a minimum of 5 minutes apart will be recorded as the baseline blood pressure. 4. Patients will also be included for consideration to enter this trial if they have known longstanding hypertension DBP >90 within 2 years of index pregnancy and/or are on antihypertensive medication, regardless of in-office blood pressure if seen in their first trimester  Significant target organ damage; at the patient's initial antepartum visit, routine serum creatinine and urine dipstick for protein are performed by the attending obstetrician. If the patient has been hypertensive by history for over 5 years, a screening electrocardiogram will be performed. These will be reviewed for results precluding participation in the trial. 1. Known renal disease creatinine > 1.2 mg/dl 2. Proteinuria >500 mg/day at baseline 3. Left ventricular hypertrophy by ECG criteria. 4. History of the following: chronic illness requiring immunosuppression, as well as secondary causes of hypertension: pheochromocytoma, hyperaldosteronism, coarctation of aorta, renal artery stenosis not revascularized
Patient description: The patients is a 25-year-old G1 P1 pregnant woman who is 24W3D gestational old who developed a sudden unset of fever and chills, accompany with nausea and vomiting. She also complains of dysuria, urgency and frequency. She also reports some severe pain in the flank. Her vital signs are: T = 39.7ºC, P = 117, R = 20, and BP = 113/74 mm Hg. Physical examination reveals tenderness on palpation of both costovertebral angles. She has no history of recurrent UTI prior to her pregnancy or any other underlying disease. The urine culture showed Gram-negative rod-shaped bacterial cells, leukocytes, and leukocyte casts. The blood culture is negative. A CBC shows Hb 12.9 g/dL, Hct 39%, MCV 76 fL, WBC count 14,120/µL.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Urinary Tract Infections Pyelonephritis Positive dipstick test for leukocyte esterase AND/OR at least 5 white blood cells per centrifuged urine sediment AND/OR at least 10 white blood cells per microliter of uncentrifuged urine outpatient or inpatient (in hospital, nursing home, or other extended-care facility) clinical diagnosis of either complicated urinary tract infection or acute pyelonephritis  Allergy or serious adverse reaction to levofloxacin, ciprofloxacin, or other fluoroquinolone urinary tract surgery or lithotripsy (treatment for kidney stones) within 7 days before study entry a second coexisting bacterial infection that requires systemic antibiotics need for a second antibiotic to treat the urinary tract infection obstruction of the urinary tract prostate infection
Patient description: The patients is a 25-year-old G1 P1 pregnant woman who is 24W3D gestational old who developed a sudden unset of fever and chills, accompany with nausea and vomiting. She also complains of dysuria, urgency and frequency. She also reports some severe pain in the flank. Her vital signs are: T = 39.7ºC, P = 117, R = 20, and BP = 113/74 mm Hg. Physical examination reveals tenderness on palpation of both costovertebral angles. She has no history of recurrent UTI prior to her pregnancy or any other underlying disease. The urine culture showed Gram-negative rod-shaped bacterial cells, leukocytes, and leukocyte casts. The blood culture is negative. A CBC shows Hb 12.9 g/dL, Hct 39%, MCV 76 fL, WBC count 14,120/µL.

Clinical trial eligibility criteria: eligible ages (years): 18.0-60.0,  Helicobacter Infections Bacterial Infections Patients diagnosed with Helicobacter pylori (H. pylori) infection patients over 45 years of age must have an endoscopic examination of the digestive system patients must have positive result of urea breath test (UBT) for H. pylori patients being treated with rabeprazole in combination with clarithromycin and amoxycillin to eradicate H. pylori  Known hypersensitivity to rabeprazole, clarithromycin, or amoxycillin evidence from endoscopic examination of gastrointestinal hemorrhage or stomach cancer, or had previous stomach surgery use of aspirin, non-steroidal anti-inflammatory drugs (NSAIDs), antibiotics, bismuth, or proton pump inhibitors during the last 4 weeks prior to study initiation history of successful treatment to eradicate H.pylori infection females who are pregnant or nursing
Patient description: The patients is a 25-year-old G1 P1 pregnant woman who is 24W3D gestational old who developed a sudden unset of fever and chills, accompany with nausea and vomiting. She also complains of dysuria, urgency and frequency. She also reports some severe pain in the flank. Her vital signs are: T = 39.7ºC, P = 117, R = 20, and BP = 113/74 mm Hg. Physical examination reveals tenderness on palpation of both costovertebral angles. She has no history of recurrent UTI prior to her pregnancy or any other underlying disease. The urine culture showed Gram-negative rod-shaped bacterial cells, leukocytes, and leukocyte casts. The blood culture is negative. A CBC shows Hb 12.9 g/dL, Hct 39%, MCV 76 fL, WBC count 14,120/µL.

Clinical trial eligibility criteria: eligible ages (years): 18.0-50.0,  Acute Uncomplicated Pyelonephritis Recent onset (less than 7 days) of costovertebral angle pain or tenderness with or without fever, and with or without lower urinary tract symptoms (dysuria, frequency, urgency). Diabetic women without long term complications of diabetes (retinopathy, nephropathy, or neuropathy) may be enrolled Stable hemodynamic status and able to tolerate oral medication Pretherapy urine culture >107 cfu/L (>104 cfu/ml) of a uropathogen (E. coli, other Enterobacteriaceae, S. saprophyticus). Patients will be enrolled into the study prior to urine culture results being known. If pretherapy cultures are subsequently not positive (usually at 48 hours), subjects will be discontinued Pyuria (> 10 wbc/mm3 or > 10 X106 wbc/L by hemocytometer; > 6-10 wbc/hpf, or > 1+ LE (leukocyte esterase) dipstick)  ·Pregnancy, breastfeeding, fluoroquinolone allergy, and any underlying structural or functional genitourinary abnormality
Patient description: The patients is a 25-year-old G1 P1 pregnant woman who is 24W3D gestational old who developed a sudden unset of fever and chills, accompany with nausea and vomiting. She also complains of dysuria, urgency and frequency. She also reports some severe pain in the flank. Her vital signs are: T = 39.7ºC, P = 117, R = 20, and BP = 113/74 mm Hg. Physical examination reveals tenderness on palpation of both costovertebral angles. She has no history of recurrent UTI prior to her pregnancy or any other underlying disease. The urine culture showed Gram-negative rod-shaped bacterial cells, leukocytes, and leukocyte casts. The blood culture is negative. A CBC shows Hb 12.9 g/dL, Hct 39%, MCV 76 fL, WBC count 14,120/µL.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Fasciitis, Necrotizing Severe Necrotizing Skin and Soft Tissue Infections Fournier's Gangrene Inclusion/   1. Read and sign the consent form. If patient is unable to sign, the consent will be obtained from a legally authorized representative. 2. Male or female > 18 years of age 3. If female of child bearing potential, negative pregnancy test 4. Surgical diagnosis of severe necrotizing fasciitis, severe necrotizing skin and soft tissue infections (e.g. Fournier's gangrene) 5. A) At least three of the following clinical signs and symptoms of local infection should be present pain out of proportion to clinical findings tenderness to palpation swelling erythema induration pus formation B) At least 1 of the two systemic conditions should be present Elevated temps.[100.4] or reduced temps. [<96] WBC counts > 12.00/cu.mm 6. Positive gram stain or wound culture obtained within 3 calendar days prior to the first dose of Daptomycin positive gram stain would gram positive cocci or gram positive rods
Patient description: The patients is a 25-year-old G1 P1 pregnant woman who is 24W3D gestational old who developed a sudden unset of fever and chills, accompany with nausea and vomiting. She also complains of dysuria, urgency and frequency. She also reports some severe pain in the flank. Her vital signs are: T = 39.7ºC, P = 117, R = 20, and BP = 113/74 mm Hg. Physical examination reveals tenderness on palpation of both costovertebral angles. She has no history of recurrent UTI prior to her pregnancy or any other underlying disease. The urine culture showed Gram-negative rod-shaped bacterial cells, leukocytes, and leukocyte casts. The blood culture is negative. A CBC shows Hb 12.9 g/dL, Hct 39%, MCV 76 fL, WBC count 14,120/µL.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Dermatitis, Atopic Must give written informed consent Must be at least 18 years of age Must have been diagnosed with atopic dermatitis fulfilling the diagnostic of Hanfin and Rajka and having active inflammation Must have a severity score of 6-9 according to Langeland and Rajka Must have a PGA of "severe" or "very severe" and a pruritus score of "moderate" or "severe" at baseline  Patients with other skin diseases that might interfere with the evaluation of AD Patients with severe diseases of other organ systems (e.g. cardiovascular, liver, kidney, psychiatric, neurologic) that might put the patient on risk during the study or might interfere with the evaluations (in the opinion of the investigator) Patient older than 65 years Systemic treatment for atopic dermatitis (e. g. corticosteroids, cyclosporine, mycophenolat-mofetil, interferon-gamma, UVB, UVA, PUVA) or systemic treatment with immunosuppressive/immunomodulating substances (e.g. azathioprin, methotrexate, biologics or hyposensitization -therapy) within 28 days prior to baseline Local treatment for atopic dermatitis with pimecrolimus/tacrolimus, steroids > class III, instable use of steroids class <III, emollients or local antiseptics/antibiotics within 14 days prior to day 1 Serious local infection (e.g., cellulitis, abscess) or systemic infection (e.g., pneumonia, septicemia) within 3 months prior to the first dose of Rituximab History of recurrent clinically significant infection Congenital or acquired immunodeficiency syndrome History of or a new diagnosis or treatment of an invasive malignancy within 5 years of enrollment. Patients with a history of treated squamous cell and/or basal cell carcinomas limited to the skin are not excluded For female patients, unless postmenopausal or surgically sterile, unwillingness to practice effective contraception, as defined by the investigator, during the study. The rhythm method is not to be used as the sole method of contraception. Female patients considering becoming pregnant while in the study are excluded
Patient description: The patients is a 25-year-old G1 P1 pregnant woman who is 24W3D gestational old who developed a sudden unset of fever and chills, accompany with nausea and vomiting. She also complains of dysuria, urgency and frequency. She also reports some severe pain in the flank. Her vital signs are: T = 39.7ºC, P = 117, R = 20, and BP = 113/74 mm Hg. Physical examination reveals tenderness on palpation of both costovertebral angles. She has no history of recurrent UTI prior to her pregnancy or any other underlying disease. The urine culture showed Gram-negative rod-shaped bacterial cells, leukocytes, and leukocyte casts. The blood culture is negative. A CBC shows Hb 12.9 g/dL, Hct 39%, MCV 76 fL, WBC count 14,120/µL.

Clinical trial eligibility criteria: eligible ages (years): 18.0-55.0,  Abortion Seekers Criteria:pregnancy equal to or less than 63 days at enrollment -  abnormal pregnancy diagnosed by ultrasound -
Patient description: The patients is a 25-year-old G1 P1 pregnant woman who is 24W3D gestational old who developed a sudden unset of fever and chills, accompany with nausea and vomiting. She also complains of dysuria, urgency and frequency. She also reports some severe pain in the flank. Her vital signs are: T = 39.7ºC, P = 117, R = 20, and BP = 113/74 mm Hg. Physical examination reveals tenderness on palpation of both costovertebral angles. She has no history of recurrent UTI prior to her pregnancy or any other underlying disease. The urine culture showed Gram-negative rod-shaped bacterial cells, leukocytes, and leukocyte casts. The blood culture is negative. A CBC shows Hb 12.9 g/dL, Hct 39%, MCV 76 fL, WBC count 14,120/µL.

Clinical trial eligibility criteria: eligible ages (years): 20.0-74.0,  Vomiting Nausea Subject with age between 20-74 years old (inclusive) of either sex Cancer subject is scheduled to receive the designated chemotherapy programs Subject without symptoms of vomiting for at least one week before dosing trial medication Subject with ECOG performance status scale no greater than 2 Subject has signed the written informed consent form  Subject has received radiotherapy to the abdomen or pelvis within 4 weeks before entering this study Subject has received the designated chemotherapy programs within 6 months before entering the study Subject has known heart failure or myocardial infraction or with laboratory abnormalities at screening Subject has known concurrent diseases that may cause vomiting Subject has taken medications that could influence the outcome of the study within 3 days before entering the study Subject with a history of allergy or intolerance to ramosetron, granisetron or dexamethasone Female subject who is pregnant or breastfeeding Subject with life expectancy less than 3 months Subject participated other investigational drug trial within 1 month before entering this study